2008
DOI: 10.1097/mph.0b013e31816356e3
|View full text |Cite
|
Sign up to set email alerts
|

Biologic Characteristics of Mesenchymal Stromal Cells and Their Clinical Applications in Pediatric Patients

Abstract: In the past few years, intensive research in the understanding of the biologic characteristics of the mesenchymal stromal cells has already led to some early clinical applications. The aim of this review is to summarize the latest information from basic science advances and the outcome of their use in clinical practice with a particular focus in pediatric patients. The minimum criteria required to identify mesenchymal stromal cells, their immunosuppressive-nonimmunogenic properties and their attribution in the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0
1

Year Published

2009
2009
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 20 publications
(16 citation statements)
references
References 84 publications
0
15
0
1
Order By: Relevance
“…[78][79][80] The use of FCS always raises concerns because of the fear of transmission of prions and still unidentified zoonoses, although FCS batches are routinely prescreened to meet the biosafety requirements of the cellular product. 81 Moreover, proteins or peptides might incorporate into MSCs during culture, thus causing immune reactions in the host, especially if more than 1 infusion is required. 82 One option is that Food and Drug Administration-approved products, such as Prochymal, Provacel, and Chondrogen, will help advance the prospects for human MSC therapy.…”
Section: Feasibility Of Human Mscs In Clinical Applicationsmentioning
confidence: 99%
“…[78][79][80] The use of FCS always raises concerns because of the fear of transmission of prions and still unidentified zoonoses, although FCS batches are routinely prescreened to meet the biosafety requirements of the cellular product. 81 Moreover, proteins or peptides might incorporate into MSCs during culture, thus causing immune reactions in the host, especially if more than 1 infusion is required. 82 One option is that Food and Drug Administration-approved products, such as Prochymal, Provacel, and Chondrogen, will help advance the prospects for human MSC therapy.…”
Section: Feasibility Of Human Mscs In Clinical Applicationsmentioning
confidence: 99%
“…Cell multipotency analysis suggested that, similarly to MSC or human PPC [Kobayashi et al, 2011], porcine PPC from the ear, as well as from the trachea, were capable of differentiating into adipocytes and osteocytes. Along this line also our isolated porcine PPC, both ePPC and tPPC, showed a spindle-like MSC phenotype [Pelagiadis et al, 2008;Rho et al, 2009].…”
Section: Discussionmentioning
confidence: 89%
“…Besides adipogenic and osteogenic differentiation, MSC are also capable of differentiating into chondrocytes [Dominici et al, 2006;Pelagiadis et al, 2008;Bahney et al, 2011;Hsu et al, 2011]. Thus, this is a cell type that is highly requested for cartilage tissue engineering, for the generation of stable cartilage free of hypertrophic growth.…”
Section: Discussionmentioning
confidence: 99%
“…in the past few years, intensive research into understanding the biological characteristics of MSCs has already shed light on some of their phenotypic markers, their immunosuppressive-non-immunogenic properties and their role in the treatment of graft-versus-host disease, in the acceleration of haematopoietic recovery and in the treatment of selected inherited diseases (Pelagiadis et al, 2008).…”
Section: Cells For Bone Tissue Engineeringmentioning
confidence: 99%